PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. DEPARTMENT OF U.S. DEPARTMENT OF U.S. DEPARTMEN

Substitute for form 1449A/PTO			Complete if Known			
			Application Number	09/509,196		
	INFORMATION D	ISCLOSURE	Filing Date	March 23, 2000		
	STATEMENT BY	APPLICANT	First Named Inventor	DALY, ROGER JOHN		
			Art Unit	1646		
(use as many sheets as necessary)			Examiner Name	CHERNYSHEV, OLGA N.		
Sheet	1	of	Attorney Docket Number	RICE-012		

			U.S. PATENT	DOCUMENTS	-
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			тідего героп
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [©]

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
BV.		Daly "The Grb7 Family of Signalling Proteins" Cell Signal (1998) 10:613-618.	
ov		Daly et al. "Cloning and Characterization of <i>GRB14</i> , a Novel Member of the GRB7 Gene Family" <i>J. Biol. Chem.</i> (1996) 271:12502-12510	
ov		Kishi et al. "Molecular cloning of human GRB-7 co-amplified with CAB1 and c-ERBB-2 in primary gastric cancer." Biochem Biophys Res Commun. (March 1997) 232(1):5-9	
ov		Lyons et al. "Identification of a novel human tankyrase through its interaction with the adaptor protein Grb14" J Biol Chem. (May 2001) 276(20):17172-80 (Epub 2001 Feb 22)	
gc		Tanaka et al. "Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma." Cancer Res. (Jan 1997) 57(1):28-31	-
ov		Stein et al. "The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer." EMBO J. (Mar. 1994) 13(6):1331-40	

Examiner Signature	alleyson	Date Considered	09/06/05
	· · · · · · · · · · · · · · · · · · ·		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known ite for form 1449A/PTO **Application Number** 09/509,196 INFORMATION DISCLOSURE Filing Date March 23, 2000 STATEMENT BY APPLICANT First Named Inventor DALY, ROGER JOHN **Art Unit Examiner Name** CHERNYSHEV, OLGA N. (use as many sheets as necessary) **Attomey Docket Number** Sheet of **RICE-012**

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T²	
oc		Margolis et al, "High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains", Proc. Natl. Acad. Sci, 1992, vol. 89, pp. 8894-8898.		
W		Janes et al., "Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7", The journal of Biological Chemistry, 1997, vol. 272, no. 13, 8490-8497		
, _				

09/06/05 Signature Considered

Date

Examiner

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.